Skip to content

Prostate cancer and an enlarged prostate together

Why they are different diseases, what prostatectomy does to urinary symptoms and what changes with each treatment.

Dr. Petronio Melo, urologistA reference in prostate cancer
CRM-SP 157.598 · RQE 70.275
Reviewed by Dr. Petronio Melo on November 19, 2026
Book a consultation
Drawing of an enlarged prostate in cross-section, seen from above, with the rectum below, benign growth nodules in the middle squeezing the urethra and a small purple focus of cancer at the back of the gland, near the rectum
On this page

Quick answer

Many men have an enlarged prostate (BPH) and prostate cancer at the same time. They are different diseases: BPH grows in the core of the gland, and most cancers start in the outer part, the peripheral zone.2,3 When the cancer is treated with radical prostatectomy, the whole prostate is removed, and BPH urinary symptoms usually improve: in a study of 1,470 men who had robotic surgery, 90.3% of those with severe symptoms improved at 1 year.6 With radiotherapy, a large prostate and urinary symptoms weigh on the choice.1 During active surveillance, BPH can be treated separately.

Two diseases in the same gland

BPH starts in the transition zone. In a classic study of 63 prostates, BPH nodules arose in a small area around the urethra, just above the point where the ejaculatory ducts join it.3 As they grow, these nodules squeeze the urethra, which causes a weak stream, urgency and trips to the bathroom at night. The page on BPH symptoms explains each one.

Cancer usually starts somewhere else. In a series of 104 prostates removed for cancer, 68% of tumors had started in the peripheral zone, 24% in the transition zone and 8% in the central zone.2 Transition zone tumors often appeared inside BPH nodules and were found at TURP.2 That is why cancer is sometimes found in the tissue removed during enlarged prostate surgery. The page on cancer found during enlarged prostate surgery explains what to do in that case.

BPH does not turn into cancer. The US National Cancer Institute states that an enlarged prostate does not increase the risk of prostate cancer.4 Some large studies found the two diseases together more often, but it is unclear whether this reflects a causal link, shared risk factors or simply more testing in men with symptoms.5 Both are common and become more frequent with age, so they often show up in the same man.

Symptoms usually come from BPH. Early prostate cancer usually causes no symptoms.4 A man with cancer who has a poor urine flow usually has it because of BPH. The IPSS questionnaire measures these symptoms and helps track improvement after treatment.

Radical prostatectomy treats both

Radical prostatectomy removes the whole prostate with the seminal vesicles. The BPH tissue comes out with it, and the urethra is no longer squeezed. Studies show the effect on urination:

  • Australian study, 1,470 men who had robotic surgery: at 1 year, 57% had a better IPSS than before surgery, and 76% had mild symptoms (IPSS of 7 or less). Among those with severe symptoms before surgery (IPSS 20 to 35), 90.3% improved.6
  • Review of 18 studies with 16,207 patients: IPSS fell by an average of 2.84 points at 12 months. The improvement in urinary quality of life was larger in men with more symptoms and bigger prostates.7

Surgery relieves the obstruction, but it also affects the sphincter and the bladder neck. In the first weeks after the catheter comes out, leakage with effort is common, and continence returns gradually. In the review, it went from about 40% to 50% in the first month to nearly 90% at 12 months.7 The page on continence after prostatectomy explains this recovery. In my practice, Kegel exercises are done before and after surgery.

Does enlarged prostate surgery treat the cancer? No. TURP, HoLEP and the other operations for an enlarged prostate remove or destroy the core of the gland and leave the peripheral zone, where most cancers arise.2 Men who have had BPH surgery and are later diagnosed with cancer can have radical prostatectomy: the page on prostatectomy after enlarged prostate surgery shows what studies found. In my practice, previous surgery does not rule it out.

Robotic prostatectomy in a large prostate

The European guideline says a larger prostate can make prostatectomy more complex, without increasing positive margins.1 Studies of large prostates removed with the robot show what changes:

  • 14,481 patients at a US center, grouped by prostate weight: above 150 grams, the nerves were fully spared less often (13.7% versus 38.3% in prostates under 50 grams), positive margins were less frequent (12.8% versus 19.3%), and continence (77.8% versus 89.5%) and erections (70.0% versus 84.1%) recovered less often.8
  • Above 150 grams, compared with similar prostates under 50 grams: there was more bleeding, longer console time and the catheter stayed longer. Complications, continence and erections showed no difference, and positive margins were less frequent.10
  • 100 grams or more, 1,555 patients at an Italian center: surgery took longer and there was more bleeding. Continence right after catheter removal was lower (42% versus 64%), and at 12 months it was the same (87% versus 88%). Positive margins did not change.9
  • 951 patients at a US center: after adjusting for other factors, prostate size did not change bleeding, margins or recovery of urinary and sexual function.11

The studies do not agree on everything, especially on continence and erections. All are retrospective and come from very experienced centers. In practice, this has to be assessed case by case, together with the size and grade of the cancer, age, and urinary and erectile function before surgery.

The European guideline also notes that men with urinary symptoms, a large prostate or previous TURP may benefit from a bladder X-ray before catheter removal, to check that the join between the bladder and the urethra has sealed.1

Median lobe in radical prostatectomy

The median lobe is the part of BPH that grows into the bladder, right at the bladder neck, where the prostate is separated from the bladder during prostatectomy. The page on the median lobe explains what it is. During surgery, it calls for extra care at that point:

  • 1,693 patients: a median lobe was present in 19%. Bleeding, complications, leakage at the join, positive margins and continence were similar. Surgery took a little longer.12
  • 9,710 patients, followed for 6 years: surgery took 119 minutes with a median lobe and 110 without it. Continence was similar, and PSA recurrence at 10 years was lower in the median lobe group.14
  • 663 patients, with a symptom questionnaire before and after: men with a median lobe started with more symptoms and improved more (5.5 points versus 3.6). In those with severe symptoms, the improvement was 15.1 points. Continence was the same.13
  • 951 patients: a median lobe increased bleeding and operating time.11

The European guideline advises caution with bladder neck preservation when there is a large median lobe, because the margin at the base of the prostate needs attention.1

Radiotherapy and brachytherapy with a large prostate

With radiotherapy, the prostate stays in place. BPH remains, and radiation can irritate the bladder and the urethra, making symptoms worse for a while.1,15 That is why a large prostate and urinary symptoms weigh on the choice:

  • Brachytherapy: for seed brachytherapy alone, the European guideline refers to men who pass urine well, with an IPSS below 12 and a maximum flow above 15 mL per second.1 In a series of 712 men, a larger prostate and more symptoms before treatment led to more early urinary side effects, and IPSS returned to its baseline value after about 12.6 months on average.15 In another series of 714 men, 8% had urinary retention, and prostate size, IPSS and how far the prostate protruded into the bladder helped predict who would.16
  • Short-course radiotherapy: the European guideline recommends avoiding it in men with severe urinary symptoms (IPSS above 19) or obstruction, with or without a median lobe.1
  • Hormones to shrink the prostate: in a trial that randomized 60 men with prostates over 50 grams before brachytherapy, 3 months of hormone blockade shrank the prostate by 35.5%, and dutasteride combined with bicalutamide by 31.7%.17 The page on hormone therapy explains these medicines.
  • TURP before brachytherapy: according to the European guideline, men who have had TURP can have brachytherapy, with at least 3 months between the two.1

In the Australian robotic prostatectomy study, the authors compared their results with the radiotherapy literature: IPSS after surgery was lower, especially in men who already had moderate or severe symptoms.6 The page surgery or radiotherapy compares the effects of each on urination, erections and the bowel.

Active surveillance with an enlarged prostate

On active surveillance, low-risk cancer is followed closely, without immediate treatment. If urination is the problem, BPH can be treated separately:

  • Medication: BPH medications can still be used. The European guideline cites a review in which finasteride and dutasteride during surveillance were associated with less cancer progression.1 These medicines lower PSA: in the PCPT trial, PSA had to be multiplied by 2 after 2 years of finasteride to keep the comparison valid.19 In my practice, in men taking finasteride or dutasteride, I always double the PSA value and ask for a PSA test before the medicine is started. The page on PSA and finasteride explains the calculation.
  • BPH surgery: in a French study of 310 men on surveillance, 62 had HoLEP because of their symptoms. Their prostates were larger (70 versus 50 grams). Men who had HoLEP left surveillance less often (18% versus 56%), and their PSA at the end of follow-up was much lower (2 versus 7.7 ng/mL).18 The authors note that surgery changes the numbers used in follow-up, such as PSA and PSA density, and that monitoring needs to be adjusted.18

After BPH surgery, the lower PSA becomes the new reference. In my practice, an abnormal PSA leads straight to a prostate MRI.

How I approach it

At the consultation, I review your PSA, MRI, biopsy, prostate size and urinary symptoms, using the IPSS. I explain what belongs to the cancer and what belongs to BPH, and we talk about the treatment that deals with both, or about treating each one in its own time.

When surgery is the right path, I always perform radical prostatectomy with the robot. I preserve the erection nerves whenever possible. I decide on lymph node removal using the Briganti nomogram, with a 7% cut-off, and when I remove the nodes, the dissection is always extended (see pelvic lymph node dissection). The hospital stay is 1 to 2 days, but discharge usually happens in less than 24 hours, still with the catheter, which stays for 7 to 10 days.

I have a PhD from the University of São Paulo Medical School and have performed more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic. If you already have a diagnosis and want another assessment, a second opinion can be done entirely online, in English, with your test results sent in advance.

Send your case

If you have an enlarged prostate and prostate cancer and would like my opinion on your case before a consultation, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.

Frequently asked questions

Can an enlarged prostate turn into cancer?

No. BPH is a benign growth, and the US National Cancer Institute states that an enlarged prostate does not increase the risk of prostate cancer.4 Some population studies have found the two diseases together more often, but it is still unclear whether there is a causal link or whether these men simply have more tests.5

I have an enlarged prostate and prostate cancer. Does radical prostatectomy treat both?

Usually, yes. Radical prostatectomy removes the whole prostate, BPH tissue included. In an Australian study of 1,470 men who had robotic surgery, 57% had better urinary symptoms 1 year later, and 90.3% of those with severe symptoms improved.6 A review of 18 studies with 16,207 patients found IPSS improvement at 12 months, larger in men with more symptoms and bigger prostates.7

Can a large prostate be removed with the robot?

Yes. The European guideline says a larger prostate makes the operation more complex, without increasing positive margins.1 In prostates of 100 grams or more, surgery took longer and there was more bleeding, and continence was slower at first and the same at 12 months.9 In practice, this has to be assessed case by case.

Does a median lobe make radical prostatectomy harder?

It makes the operation a little longer. In a study of 9,710 patients, surgery took 119 minutes with a median lobe and 110 without it, and continence was similar.14 In another study of 663 men, those with a median lobe had a larger improvement in urinary symptoms.13

Does enlarged prostate surgery (TURP or HoLEP) treat the cancer?

No. These operations remove the core of the gland, the transition zone, and leave the peripheral zone, where most cancers arise, 68% in a classic series of removed prostates.2 Cancer that needs treatment is treated with radical prostatectomy, radiotherapy or another cancer treatment.

With a large prostate and urinary symptoms, does radiotherapy make urination worse?

It can. In a series of 712 men treated with brachytherapy, a larger prostate and more symptoms before treatment led to more urinary side effects.15 The European guideline keeps brachytherapy alone for men who pass urine well and advises caution with short-course radiotherapy in men with severe symptoms or obstruction.1 Hormone therapy can shrink the prostate by about a third before brachytherapy.17

I am on active surveillance and my urine flow is poor. Can I treat the BPH?

Yes. BPH can be treated separately, with medication or surgery. In a French study of 310 men on active surveillance, the 62 who had HoLEP left surveillance less often, 18% versus 56%, and ended up with lower PSA, which changes how follow-up is done.18

Who operates on prostate cancer with an enlarged prostate in São Paulo?

I do. I am a urologist and robotic surgeon in São Paulo, Brazil, with a PhD from the University of São Paulo Medical School and more than 1,500 robotic and laparoscopic operations, more than 500 of them robotic. I always perform radical prostatectomy with the robot. The first consultation can be online, in English.

References

  1. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer: treatment. European Association of Urology; 2026. EAU
  2. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;12(12):897-906. PubMed
  3. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978;15(4):340-345. PubMed
  4. National Cancer Institute. Understanding Prostate Changes: A Health Guide for Men. 2024. NCI
  5. Ørsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol. 2013;10(1):49-54. PubMed
  6. Ahn T, Roberts MJ, Strahan A, et al. Improved lower urinary tract symptoms after robot-assisted radical prostatectomy: implications for survivorship, treatment selection and patient counselling. BJU Int. 2019;123 Suppl 5:47-53. PubMed
  7. Marimpietri FS, Tourinho-Barbosa R, Roldan-Testillano R, et al. Lower urinary tract symptoms after robot-assisted radical prostatectomy: a systematic review. J Robot Surg. 2025;20(1):23. PubMed
  8. Jaber AR, Moschovas MC, Saikali S, et al. Impact of Prostate Size on the Functional and Oncological Outcomes of Robot-assisted Radical Prostatectomy. Eur Urol Focus. 2024;10(2):263-270. PubMed
  9. Maltzman O, Tappero S, Caviglia A, et al. Prostate size ≥ 100 g and its association with long-term outcomes of Retzius-sparing robot-assisted radical prostatectomy. World J Urol. 2024;42(1):283. PubMed
  10. Gamal A, Moschovas MC, Jaber AR, et al. Functional and Oncological Outcomes of Very Large Prostate Sizes Post Robotic Radical Prostatectomy: A Propensity Score-Matched Analysis. Prostate. 2025;85(5):456-462. PubMed
  11. Huang AC, Kowalczyk KJ, Hevelone ND, et al. The impact of prostate size, median lobe, and prior benign prostatic hyperplasia intervention on robot-assisted laparoscopic prostatectomy: technique and outcomes. Eur Urol. 2011;59(4):595-603. PubMed
  12. Coelho RF, Chauhan S, Guglielmetti GB, et al. Does the presence of median lobe affect outcomes of robot-assisted laparoscopic radical prostatectomy? J Endourol. 2012;26(3):264-270. PubMed
  13. Martinez O, Murphy C, Bsatee A, Abaza R. Impact of median lobe on urinary function after robotic prostatectomy. Prostate. 2021;81(12):832-837. PubMed
  14. Sharma R, Ozawa Y, Moschovas MC, et al. Impact of Intraoperative Enlarged Median Lobe on Functional Recovery Following Robot-Assisted Radical Prostatectomy: A Retrospective Cohort Analysis. Prostate. 2025;85(14):1342-1351. PubMed
  15. Keyes M, Miller S, Moravan V, et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys. 2009;73(4):1023-1032. PubMed
  16. Roeloffzen EM, van Vulpen M, Battermann JJ, et al. Pretreatment nomogram to predict the risk of acute urinary retention after I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2011;81(3):737-744. PubMed
  17. Gaudet M, Vigneault É, Foster W, et al. Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer. Radiother Oncol. 2016;118(1):141-147. PubMed
  18. Bâcle C, Seizilles De Mazancourt E, Abid N, et al. Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms. Prostate. 2025;85(11):989-999. PubMed
  19. Etzioni RD, Howlader N, Shaw PA, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol. 2005;174(3):877-881. PubMed

Would you like to talk about your case?

In the consultation, I go over your tests and your priorities.

Book a consultation5.0186 Google reviews

Related guides